AERVYN Klow peptide pen, 80 mg / 3 mL, with its carton

Photograph · Pen and cartonLot AV-KLW-2609-A

Klow

GHK-Cu + BPC-157 + TB-500 + KPV · 80 mg / 3 mL

In stockResearch use onlyRecovery & repair
£340

VAT included · 1 pen · 80 mg / 3 mL

1

Sold for research use only. Not a medicine and not authorised for human consumption. Purchasers must be 18+ and confirm intended use at checkout.

  • Ships chilled · same-day dispatch before 2 pm
  • Free UK shipping over £300

About

What this is

KLOW combines GHK-Cu, BPC-157, TB-500 and KPV in a broad experimental formulation spanning tissue response, extracellular matrix, skin biology and barrier-signalling research. Supplied by the manufacturer as a pre-filled 80 mg / 3 mL dose-dial pen for research use — no reconstitution, no vials, no drawing up. Our evidence records for each component are linked below and graded on the same scale as every compound on this site.

  • 01Pre-filled pen — no reconstitution
  • 02Identity confirmed by LC-MS per lot
  • 03Purity ≥ 99% by HPLC per component
  • 04Certificate published against the lot number

Specification

What's in the pen

ContentsGHK-Cu 50 mg · BPC-157 10 mg · TB-500 10 mg · KPV 10 mg
Concentration26.7 mg/mL (combined)
FormatPre-filled dose-dial pen · 3 mL · 80 mg total
ClassGHK-Cu + BPC-157 + TB-500 + KPV blend
Purity≥ 99% per component (HPLC)
List priceAED 1,650 · converted at a fixed rate
DiallingDose-dial pen with a numbered window; the dial sets the volume delivered per actuation.
StorageRefrigerate at 2–8 °C. Do not freeze. Keep the cap on and the pen out of direct light between uses.
In the box1 × pre-filled 3 mL pen · lot-numbered outer carton · certificate of analysis · pen-needle compatibility note
Updated26 September 2026
Components of Klow
ComponentAmountWhat it isEvidence · Skin
GHK-Cu50 mgCopper-binding tripeptideLimitedRecord
BPC-15710 mgSynthetic pentadecapeptideNot graded for this goalRecord
TB-50010 mgSynthetic thymosin β4 fragment (residues 17–23)Not graded for this goalRecord
KPV10 mgAnti-inflammatory tripeptide (α-MSH fragment)InsufficientRecord

Amounts are per pen. Where the composition states no split, the component amounts are on the lot certificate.

Device

How the pen works

  1. 01

    Attach a pen needle

    Take the cap off, wipe the septum with an alcohol swab and screw a compatible pen needle on until it seats. Use a fresh needle every time and never share a pen.

  2. 02

    Prime

    Dial a small test amount, hold the pen needle-up and press the button until a drop appears at the tip. This clears air from the needle and confirms the pen delivers.

  3. 03

    Dial

    Turn the dial to the volume you intend to deliver; the window shows the setting in the pen's increments. The dial sets a volume of solution — nothing more.

  4. 04

    Inject

    Insert as the pen-needle instructions describe, press the button fully and hold for ten seconds before withdrawing. Remove and bin the needle in a sharps container, recap and refrigerate.

Dosing is not provided; see the research information in the evidence record. These steps describe how the device operates, not how or whether to use its contents.

Certificate of analysis · 4 components tested

Lot AV-KLW-2609-A

BatchAV-KLW-2609-A
Tested on4 September 2026
LaboratoryJanoshik Analytical
Purity · per component≥ 99.0% each component (HPLC)
IdentityAll components confirmed (LC-MS)
Endotoxin< 0.5 EU/mg

Independent test of a sample from lot AV-KLW-2609-A of Klow. Each component is identified by LC-MS and its purity reported separately; endotoxin is measured on the finished solution. Testing says what is in the pen, not whether the combination is safe or does anything in people. How we test

Evidence record · reviewed 16 Sept 2026 · 4 components

What the research says about each component

Each component has its own record. The combination in this pen has not been studied in people, so the grades below are per component, not for the blend.

GHK-Cu

Copper-binding tripeptide

Topical copper peptide with modest cosmetic data; injectable use is untested.

Overall evidence
Limited
Human evidence
Topical cosmetic use
Regulatory · jurisdictions on record
Not authorised
  • Not authorised · United Kingdom, United States, European Union, Australia and Canada
  • United Kingdom · Not authorised as a medicine; permitted as a topical cosmetic ingredient. · reviewed 1 Sept 2026
Anti-doping · WADA
Not on the Prohibited List
GHK-Cu evidence record

GHK-Cu + BPC-157 · Not studied together in people

No human data on the combination, and no human data on injected GHK-Cu alone.

BPC-157

Synthetic pentadecapeptide

Widely sold 'healing peptide' with animal data but no published human trials.

Overall evidence
Insufficient
Human evidence
Animal / laboratory data only
Regulatory · jurisdictions on record
Not authorised
  • Not authorised · United Kingdom, United States, European Union, Australia and Canada
  • United Kingdom · No marketing authorisation; sold online as a 'research chemical'. · reviewed 1 Sept 2026
Anti-doping · WADA
Prohibited at all times

Relevant if you compete in tested sport.

BPC-157 evidence record

BPC-157 + TB-500 · Not studied together in people

The most commonly co-marketed 'healing stack'. There are no human data for either peptide alone, let alone together; combining two angiogenic agents of unknown purity compounds the uncertainty rather than the benefit.

TB-500

Synthetic thymosin β4 fragment (residues 17–23)

Thymosin β4 fragment sold for healing; no human trials of the fragment.

Overall evidence
Insufficient
Human evidence
Animal / laboratory data only
Regulatory · jurisdictions on record
Not authorised
  • Not authorised · United Kingdom, United States, European Union, Australia and Canada
  • United Kingdom · No marketing authorisation; sold online as a 'research chemical'. · reviewed 1 Sept 2026
Anti-doping · WADA
Prohibited at all times

Relevant if you compete in tested sport.

TB-500 evidence record

TB-500 + KPV · Not studied together in people

Blended together in the Klow pen. No human data on the combination; TB-500 has no human data at all and KPV has none by any route.

KPV

Anti-inflammatory tripeptide (α-MSH fragment)

α-MSH tripeptide with anti-inflammatory animal data and no human trials.

Overall evidence
Insufficient
Human evidence
Animal / laboratory data only
Regulatory · jurisdictions on record
Not authorised
  • Not authorised · United Kingdom, United States, European Union, Australia and Canada
  • United Kingdom · No marketing authorisation; sold online as a 'research chemical'. · reviewed 16 Sept 2026
Anti-doping · WADA
Not on the Prohibited List
KPV evidence record

Fit

Who this is for

Skin and surface repair with an inflammatory component — the broadest blend in the range.

  • Skin quality plus slow-healing marks, scars or irritation
  • Repair goals where inflammation is part of the picture
  • Wanting skin and recovery support in one pen

Check your fit

The Peptide Checkup maps your goal and history against the evidence for this pen and tells you if it is a poor fit — even after you have bought it.

Check your fit · 7 minutes

Also in the range · by shared goal, then bestsellers

5 related pens

View all 24
  • AERVYN Wolverine peptide pen, 40 mg / 3 mL, with its carton

    Wolverine

    BPC-157 + TB-500 · 40 mg / 3 mL

    £235
  • BPC-1571 PEN · 10 MG / 3 MLIllustration — photo to follow

    BPC-157

    Peptide pen · 10 mg / 3 mL

    £170
  • AERVYN GHK-Cu peptide pen, 100 mg / 3 mL, with its carton

    GHK-Cu

    Peptide pen · 100 mg / 3 mL

    £215
  • AERVYN Glow peptide pen, 70 mg / 3 mL, with its carton

    Glow

    GHK-Cu + BPC-157 + TB-500 · 70 mg / 3 mL

    £295
  • AERVYN KPV peptide pen, 10 mg / 3 mL, with its carton

    KPV

    Peptide pen · 10 mg / 3 mL

    £175